BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CCMG | CCGM - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://ccmg.51-222-78-205.ygkweb.ca
X-WR-CALDESC:Events for CCMG | CCGM
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240628T120000
DTEND;TZID=America/Toronto:20240628T130000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20240626T165750Z
UID:10000040-1719576000-1719579600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nNew \nAs of March 2024\, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. \nNote\, to obtain credit for this CPD activity\, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent. \n \n  \n  \nAdvancing Clinical Genetics Education in Canada: Current Practices and Emerging Needs \nSpeaker: Dr. Hanna Faghfoury \nBio \nDr. Hanna Faghfoury is a clinical and metabolic geneticist at Mount Sinai Hospital and University Health Network in Toronto as well as an Associate Professor and clinician teacher at the University of Toronto. She has led numerous roles within undergraduate and postgraduate genetics education at Sickkids and at the University of Toronto\, and currently directs the Medical Genetics and Genomics residency program and the Canadian College of Medical Geneticist (CCMG) fellowship programs in both Clinical genetics and Biochemical genetics. Most recently\, she was appointed Expert lead in Inherited Metabolic Disorders at Ontario Health where her team aims to enhance access to care for patients and families with inherited metabolic conditions.  \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2024-06-28/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240531T120000
DTEND;TZID=America/Toronto:20240531T130000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20240527T133756Z
UID:10000039-1717156800-1717160400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nNew \nAs of March 2024\, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. \nNote\, to obtain credit for this CPD activity\, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent. \n \n  \n  \nTitle: Development of Gene Therapy for GM2 Gangliosidosis and Creatine Deficiency Disorders \nIt is all about developing gene therapies for genetic conditions. \nLearning objectives: \n\nDefine ‘Gene Therapy’.\nList at least three factors affecting gene therapy outcomes.\nList at least three conditions that can be treated by gene therapy- approved products.\nList at least three ethical issues with gene therapy.\n\n \n  \nSpeaker: Dr. Jagdeep Walia \nBio \nDr. Jagdeep Walia is a medical geneticist and full-time professor in the Division of Medical Genetics\, Department of Pediatrics. A medical school graduate from India\, he finished his residency in Medical Genetics from University of Manitoba and then joined Queen’s University in 2012 as a clinical Geneticist. \nDr. Walia’s research lab focuses on developing novel gene therapy approaches for inherited and acquired neurodegenerative disorders. His focus is on GM2 gangliosidoses\, creatine deficiency disorders\, galactosemia and 2 rare autism spectrum disorders. The translational nature of this work is exemplified by the initiation of a phase 1/2 clinical trial for infantile GM2 gangliosidoses at Queen’s University/Kingston Health Sciences Centre using adeno-associated virus vector (AAV) as a tool for gene transfer to the central and peripheral nervous system. He has published more than 50 peer-reviewed articles and has been invited as a speaker on the topic of gene therapy for local\, national and international conferences. \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2024-05-24/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240322T120000
DTEND;TZID=America/Toronto:20240322T130000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20240402T175721Z
UID:10000038-1711108800-1711112400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nNew \nAs of March 2024\, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. \nNote\, to obtain credit for this CPD activity\, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent. \n \n  \n  \nGenetic Medicine For Rare Neurogenetic Disease \nIn this presentation\, I will summarize the current state of the field of genetic medicine approaches for neurogenetic disease. I will focus on gene therapy\, and talk about its advantages and challenges. \nLearning objectives: \n\nIdentify the benefits and challenges of gene therapy for neurogenetic disease.\nAssess the emerging genetic medicine approaches for treating neurogenetic conditions.\n\nSpeaker:\nDr. Jim Dowling \nBio \nDr. Jim Dowling is a staff clinician and senior scientist at the Hospital for Sick Children and a Professor of Paediatrics and Molecular Genetics at the University of Toronto. He is also the Mogford Campbell Family Chair of Paediatric Neuroscience. Dr. Dowling received his BSc and MSc from Yale University\, his MD/PhD from the University of Chicago\, and did his residency in child neurology at Children’s Hospital of Philadelphia. \nDr. Dowling’s clinical expertise is in childhood neurogenetic disorders. His research examines questions of disease pathogenesis and therapy development for congenital muscle diseases. In addition to his research program\, he currently serves as board chair of TREAT NMD\, as an executive board member of the World Muscle Society\, and as the pediatric lead of the NMD4C pan-Canadian neuromuscular network. He was recently honored to receive the Researcher of the Year Award from Muscular Dystrophy Canada. \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023 – cancelled\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2024-03-22/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240223T120000
DTEND;TZID=America/Toronto:20240223T130000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20240220T175337Z
UID:10000037-1708689600-1708693200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \n \n  \n  \nTitle: A Clinician’s Guide to Preimplantation Genetic Testing \nWe aim to introduce the concepts of preimplantation genetic testing\, including for aneuploidy\, structural rearrangements\, and monogenic disorders. We will outline potential benefits\, limitations\, and risks associated with preimplantation genetic testing and demonstrate clinical utility through case examples. \nLearning objectives: \n\nIdentify the potential benefits and limitations of preimplantation genetic testing technology.\nDistinguish between the types of preimplantation genetic testing and eligibility criteria for each.\nConsider patient populations who would benefit from preimplantation genetic testing to integrate into clinical practice.\n\nSpeakers: \nTami Uster \nTami Uster is Canadian and American Board Certified Genetic Counsellor with Mount Sinai Hospital’s Prenatal Diagnosis and Medical Genetics Program and Mount Sinai Fertility. Tami graduated from the Genetic Counselling graduate program at Wayne State University in 2005 and has a specialty in prenatal diagnosis and infertility. \nEmma Blanche \nEmma Blanche (she/her) works as a board-certified genetic counsellor at Mount Sinai Fertility. She graduated from the Masters of Genetic Counselling program at Wayne State University in 2022. \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023 – cancelled\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2024-02-23/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240126T120000
DTEND;TZID=America/Toronto:20240126T130000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20240119T175405Z
UID:10000036-1706270400-1706274000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \n \n  \n  \nTitle: Novel Outcome Measures For Genomic Medicine \nThis presentation will describe a framework for outcome measurement in genomic medicine\, highlighting the complexities associated with defining the notion of value in this context. Since the value of genomic testing depends upon perspective and clinical context\, this presentation will summarize ongoing work to develop and validate novel measures of utility from clinician and patient perspectives. \nLearning objectives: \n\nDescribe a multi-dimensional framework for outcome measurement in genomic medicine.\nUnderstand a methodological approach for developing and validating outcome measures.\nConsider the application of novel outcome measures for a range of clinical genetics settings.\n\nSpeaker: Dr. Robin Hayeems \nBio \nDr. Robin Hayeems is a Senior Scientist in Child Health Evaluative Sciences (CHES) at The Hospital for Sick Children (SickKids) and an Associate Professor in the Institute of Health Policy\, Management and Evaluation (IHPME) at the University of Toronto. She is trained in genetic counselling (ScM\, Johns Hopkins University)\, public health and bioethics (PhD\, University of Toronto)\, health policy research (University of Toronto\, IHPME Postdoctoral Fellowship) and health services research (University of Toronto\, Institute for Clinical and Evaluative Sciences Postdoctoral Fellowship).Using applied health services and policy research methods\, Robin’s work focuses on the delivery\, evaluation\, and governance of genomic screening and diagnostic tools in the prenatal\, newborn\, and early childhood periods. As a member of several provincial advisory committees\, her work informs and is informed by policy development in this area. Robin holds a Canada Research Chair (Tier 2) in Genomics and Health Policy. \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023 – cancelled\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2024-01-26/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20231215T123000
DTEND;TZID=America/Toronto:20231215T133000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20231211T173533Z
UID:10000035-1702643400-1702647000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \n \n  \n  \nTitle: Discerning Diversity: The Role of Data in Advancing Health Equity from a Genetics Perspective \nIn this presentation\, we will explore how we can leverage sociodemographic data to advance health equity. We will unpack the challenges related to the ethical collection\, use and interpretation of data for use in equity initiatives. We will also propose actionable strategies for addressing disparities and building inclusive clinical genetics health services. \nLearning objectives: \n\nDefine and distinguish between race\, ethnicity\, ancestry and other identifiers used in data collection and reporting.\nEvaluate the impact of race-based data collection on clinical decision-making.\nUnderstand different strategies to support appropriate use of data from equity-seeking communities.\n\nSpeaker: Muna Aden \nBio \nMuna Aden is a dedicated public health professional with thirteen years of experience in health equity research. She currently serves as the Equity Lead for the Provincial Genetics Program at Ontario Health. She earned an undergraduate degree from McMaster University in Health Studies and Psychology and holds a Master of Public Health from the University of Waterloo. She previously held the position of Research Officer at the University of Toronto where she coordinated Indigenous health equity research studies. She is passionate about knowledge exchange and advancing health equity and has collaborated with community leaders\, health care providers and policymakers to implement evidence-based interventions for equity-deserving communities. \nMuna regularly engages in capacity sharing initiatives and strives for the greater representation and meaningful involvement of community members in policy development. \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2023-12-22/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20231124T120000
DTEND;TZID=America/Toronto:20231124T130000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20231123T185801Z
UID:10000034-1700827200-1700830800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \n \n  \n  \nRedevelopment Work in BC’s Provincial Medical Genetics Program \nThe presentation will focus on features of the Handra et al.\, (2023) publication. This will be contextualized in discussions of our program’s redevelopment work\, which aims to improve our internal program\, its resources\, and our collaborations. \nLearning objectives: \n\nConsider an initiative to refresh and grow a province’s clinical genomics capacity.\nDescribe use of process mapping and an electronic QI platform.\nDiscuss use of articulating explicit principles\, frameworks\, policies\, evaluation.\nReflect on progresses and what we envision next in our redevelopment initiative\, with attention on how our program is similar and different to others in Canada\, with goals of building program identity/shared vision and resources within the program\, as well as engage and enable other (potential) contributors to genomics care.\n\nSpeaker:\nDr. Linlea Armstrong \n \nBio\nDr. Linlea Armstrong is a medical geneticist and currently medical director for BC’s Provincial Medical Genetics Program. Dr. Armstrong maintains a general medical genetics practice\, with special interests in the application of next generation sequencing to rare disease care\, as well as in the diagnosis of pediatric tumour and cancer predisposition\, and differences of sexual development. One of the most exciting parts of the medical directorship has been her program’s collaboration with the lab in setting up our Genome Sequencing BC service. Dr. Armstrong has a passion for medical education and quality improvement\, and over time has served in leadership roles with UBC’s Medical Genetics and Genomics Royal College residency program\, Masters of Genetic Counselling program\, and Vancouver Fraser Medical Program’s Faculty Development team. \n  \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023 – cancelled\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2023-11-24/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20231027T120000
DTEND;TZID=America/Toronto:20231027T130000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20231016T150753Z
UID:10000033-1698408000-1698411600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series (cancelled)
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \n  \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023 – cancelled\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2023-10-27/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230929T120000
DTEND;TZID=America/Toronto:20230929T130000
DTSTAMP:20260626T141116
CREATED:20230927T144256Z
LAST-MODIFIED:20240402T175757Z
UID:10000032-1695988800-1695992400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nNew \nAs of March 2024\, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. \nNote\, to obtain credit for this CPD activity\, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent. \n \n  \n  \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023 – cancelled\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230630T120000
DTEND;TZID=America/Toronto:20230630T130000
DTSTAMP:20260626T141116
CREATED:20220902T211051Z
LAST-MODIFIED:20230626T144431Z
UID:10000016-1688126400-1688130000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series June 2023
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nClick HERE to register. \nCCMG Position Statement: Genetic And Metabolic Investigations For Patients With Neurodevelopmental Disorders \nThe co-chairs of the CCMG working group to develop a guideline for genetic and metabolic investigations for patients with NDDs will discuss the process and results. A national multidisciplinary working group developed a position statement for the genetic and metabolic investigation of patients with neurodevelopmental disorders (NDDs). The impetus for this guideline\, the methodology and process for its development and key recommendations will be presented. \nLearning Objectives: \n\nUnderstand the impetus for a Canadian guideline for genetic and metabolic investigation of neurodevelopmental disorders (NDDs)\nDescribe and apply methodologies for guideline development\nPlan an investigation for patients with neurodevelopmental disorders\n\nSpeakers \nDr. Melissa Carter\nDr. Hilary Vallance \nBios \n \n  \nDr. Melissa Carter is a clinical geneticist at CHEO in Ottawa\, specializing in neurodevelopmental disorders. She completed her residency in Ottawa and then a fellowship in developmental pediatrics in Toronto. She is the co-chair of a CCMG working group to develop guidelines for etiological investigations for patients with neurodevelopmental disorders\, and is currently the Clinical Lead of the Neurodevelopmental Genetics expert group at Ontario Health. \n  \n \n  \nDr. Hilary Vallance is a Medical Biochemist / Biochemical Geneticist at BC Children’s Hospital who obtained her MD from the University of British Columbia (UBC). She completed a residency in Medical Biochemistry at UBC followed by fellowship training in Biochemical Genetics. She is the Director of the BC Newborn Screening Program. Her research contributions have been in the area of inborn errors of metabolism and newborn screening for treatable conditions. \n  \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-june-2023/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230526T120000
DTEND;TZID=America/Toronto:20230526T130000
DTSTAMP:20260626T141116
CREATED:20220902T210950Z
LAST-MODIFIED:20230512T155842Z
UID:10000015-1685102400-1685106000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series May 2023
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Health Impact Of Founder Mutations In The French Canadian Population Of Quebec: A Historical Perspective \nWe will review the demographic history of the European settlement of Quebec. We will discuss the major regional differences in settlement histories. We will demonstrate how demographic and historical factors have influenced the differential frequencies of genetic conditions in Quebec in particular of neurogenetic diseases. \nLearning objective: \nConsider the impact of shared genetic heritage on the different regional frequencies of genetic diseases in Quebec. \nSpeaker: Dr. Bernard Brais \nBio \nBernard Brais MD MPhil PhD is a neurogeneticist and historian of medicine\, Professor of Neurology and Genetics at McGill University and Director of the Rare Neurological Diseases group of the Montreal Neurological Institute. His research largely focuses on the genetic basis of rare neuromuscular disorders with founder effects in Quebec. He has played an leading role in the identification of the first mutations in the genes responsible for Oculopharyngeal Muscular Dystrophy (OPMD\, PABPN1)\, Hereditary Sensory and Sensory Neuropathy type 2A (HSAN2A\, WNK1)\, Limb girdle muscular dystrophy Recessive 12 (LGMDR12\, ANO5)\, Hypomyelinating Leukodystrophy types 7 and 8 (HLD7 and HLD8\, POLR3A and POLR3B)\, Dominant NAGLU neuropathy\, congenital core ZAK myopathy and FGF14/SCA27B GAA repeat expansion in late ataxias. \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-may-2023/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230428T120000
DTEND;TZID=America/Toronto:20230428T130000
DTSTAMP:20260626T141116
CREATED:20220902T210851Z
LAST-MODIFIED:20230420T213232Z
UID:10000014-1682683200-1682686800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series April 2023
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nTandem DNA Repeat Expands our Understanding of Complex Disorders  \nObjectives: \n\nIdentify tandem repeat expansions from short-read genome sequence data.\nAssess the contribution of tandem repeat expansions in complex disorders.\nConsider analyzing tandem repeats in other genetic disorders.\n\nDescription:\nIdentification of genetic risk factors has provided important information on understanding the functional pathways involved in many of complex disorders. However\, the contributing genetic factors identified in many complex disorders so far generally confer less risk than expected from the empirical estimates of their heritability. Tandem DNA repeats make up around 6% of the human genome and have been associated with more than 50 monogenic disorders\, but their involvement in complex disorders is largely unknown. I will present our novel approach to detect genome-wide tandem repeat expansions. This approach has led to the identification of rare tandem repeat expansions contributing to autism spectrum disorder and other conditions. It provides a model to search for missing heritability in other complex disorders. \n \nSpeaker:\nDr. Ryan Yuen \nBio \nDr. Ryan Yuen is a Senior Scientist in Genetics & Genome Biology Program at The Hospital for Sick Children\, and an Assistant Professor in Department of Molecular Genetics at the University of Toronto. His research focuses on exploiting whole genomescanning methodologies to dissect the underlying genetic architecture in complex disorders. \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-april-2023/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230331T120000
DTEND;TZID=America/Toronto:20230331T130000
DTSTAMP:20260626T141116
CREATED:20220902T210752Z
LAST-MODIFIED:20230329T153119Z
UID:10000013-1680264000-1680267600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series March 2023
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nGenetic Test Interpretation from Pathogenicity to Variant Function\nDr. Las will present approaches to interpret clinical genetic tests of patients with neurodevelopmental disorders and epilepsy\, while considering variant pathogenicity and function.\nObjectives: \n\nIdentify the current status of genetics in neurodevelopmental disorders.\nAssess the use of genetic testing.\nConsider patient selection for precision medicine trials.\n\nSpeaker – Dr. Dennis Lal\nBio\nThe Lal Research Group focuses on the discovery\, evaluation\, and translation of biomarker into clinical care. Specifically\, we aim to develop computational methods which integrate large genetic\, clinical\, and biological data sets to improve the prediction of patient outcomes – paving the way for personalized medicine. \nDennis is Assistant Professor in the Department of Molecular Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) and Assistant Staff in the Genomic Medicine Institute with a secondary staff appointment in the Neurological Institute’s Epilepsy Center both Cleveland\, US. In addition to his primary appointments in Cleveland\, he is Visiting Scientist at the Broad Institute of Harvard and M.I.T.\, Cambridge\, US as well as Group Leader at the Cologne Center for Genomics\, Cologne\, Germany. \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-march-2023/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230224T120000
DTEND;TZID=America/Toronto:20230224T130000
DTSTAMP:20260626T141116
CREATED:20220902T210651Z
LAST-MODIFIED:20230221T220055Z
UID:10000012-1677240000-1677243600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series February 2022
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nReconsidering Reproductive Carrier Screening\nA review of the tennets of reproductive carrier screening and points to provoke thought into what can be done better. A presentation of an update on advances of reproductive carrier screening. \nLearning Objectives \nConsider the rationale for carrier screening and different approaches\n– Compare the current practice in Canada vs elsewhere\n– Describe what has changed the landscape\n– Critique the pros and cons of panethnic and expanded carrier testing\n– Discuss where to go from her \nSpeakers bios \nDr. Joanna Lazier – Joanna Lazier is a Medical Geneticist at CHEO in Ottawa. She has a longstanding interest in prenatal and perinatal Genetics\, and founded the Prenatal Genetics Clinic in Edmonton. Upon moving to Ottawa in 2018\, she has become actively involved in prenatal and perinatal Genetics within the province of Ontario\, and is the chair of Prenatal Screening Ontario’s Genetics Working Group\, and the primary author of the CCMG position statement for the clinical application of fetal genome-wide sequencing during pregnancy. She is the chair of the CCMG Clinical Practice committee and co-chair of the CCMG Working Group on Reproductive Genetic Screening. \nDr. Ritu Aul – Dr. Aul is a Medical Geneticist who has been practicing in the GTA for more than 12 years. She completed her Medical Genetics residency at the University of British Columbia after medical school at Queen’s University. Dr. Aul has a special interest in prenatal screening and prenatal diagnosis. She currently sits on the CCMG Clinical Practice committee and co-chairs a working group with Dr. Lazier on updating current national guidelines for Reproductive Carrier Screening. \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-february-2022/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230127T120000
DTEND;TZID=America/Toronto:20230127T130000
DTSTAMP:20260626T141116
CREATED:20220902T210601Z
LAST-MODIFIED:20230125T221946Z
UID:10000011-1674820800-1674824400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series January 2023
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nJanuary 27\, 2023 – New Adventures in Neurogenetics \nDr. James Dowling\, Senior Scientist\, Program of Genetics and Genome Biology\nThe Hospital for Sick Children\nStaff Clinician\, Division of Neurology\, The Hospital for Sick Children\nProfessor\, Departments of Paediatrics and Molecular Genetics\, University of Toronto \n  \n  \n  \n  \n  \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-january-2023/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221216T123000
DTEND;TZID=America/Toronto:20221216T133000
DTSTAMP:20260626T141116
CREATED:20220902T211245Z
LAST-MODIFIED:20221206T204803Z
UID:10000017-1671193800-1671197400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series December 2022
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nOverview of Diversity in Genomics Research and Medicine\nThis talk will provide an overview of diversity in genomics research and medicine\, including representation from different social and cultural groups. We will discuss the history and definitions of “race”\, “ethnicity”\, and “ancestry” as well as their current uses in genetics and genomic medicine. Audience members will reflect on their own work and deliberate best practices related to the use of population descriptors as categorical variables.\n\nLearning Objectives – by the end of this session\, attendees will be able to:\n\n\nIdentify conceptual issues related to the use of categorical population descriptors in genetics and genomic medicine.\nAssess current practices in clinical genetics research and medicine around the use of race\, ethnicity\, and ancestry.\nDecide on appropriate and inappropriate applications of population descriptors in future work.\n\n\nAlice Popejoy\, Epidemiology \n  \nSpeaker:\nDr. Alice Popejoy \nBio\nAlice Popejoy\, Ph.D. is an Assistant Professor in the Epidemiology Division of the Department of Public Health Sciences at the University of California\, Davis (UC Davis Health). She is also an Associate Member of the UC Davis Comprehensive Cancer Center. Dr. Popejoy’s research program in public health genetics is situated at the intersections of evolutionary genomics\, biomedical data science\, statistical genetics\, and the attending ethical\, legal\, and social implications (ELSI). She is currently focused on innovation and methods development to fundamentally shift the way human populations are categorized in biomedical research\, epidemiology\, and precision medicine. She received her B.A. from Hamilton College and her Ph.D. in public health genetics from the University of Washington. \n  \n  \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-december-2022/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221125T120000
DTEND;TZID=America/Toronto:20221125T130000
DTSTAMP:20260626T141116
CREATED:20220902T210407Z
LAST-MODIFIED:20221117T215238Z
UID:10000010-1669377600-1669381200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series November 2022
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register. \n  \nTitle: Hereditary Cancer Surveillance Using Cell-Free DNA Sequencing \nCarriers of hereditary cancer syndromes are at heightened risk for malignancy and therefore undergo annual clinical screening for a host of cancers. As cancers are now well-known to shed cell-free DNA into the blood stream\, we founded the CHARM consortium (Cell-free DNA in Hereditary and High-risk Malignancies\, www.charmconsortium.ca) to assess whether regular genome and methylome profiling of blood plasma can detect the earliest cancers in this population. In this talk\, I will discuss findings from multiple different types of hereditary cancer syndromes utilizing a combination of mutational\, fragmentomic\, and epigenetic approaches to cell-free DNA analysis. I will also introduce data sharing and analytic strategies to increase the sensitivity and impact of these techniques. I will also provide an update on the current activities and future directions of the CHARM consortium. \nLearning objectives: \n\nUnderstand some of the challenges with the collection\, generation\, and interpretation of liquid biopsy data in clinical studies.\nDescribe different biological aspects of cell-free DNA and associated technologies to detect early cancer.\nIdentify opportunities in hereditary cancer to assess the use of cell-free DNA sequencing technologies for cancer screening.\n\n \nDr. Trevor Pugh PhD\, FACMG \nBio \nDr. Trevor Pugh\, PhD\, FACMG is a cancer genomics researcher\, board-certified molecular geneticist\, and holder of the Canada Research Chair in Translational Genomics. He is Director of the Joint Genomics Program of the University Health Network and Ontario Institute for Cancer Research which delivers basic\, translational\, and clinically-accredited genomics services. He is also appointed as Associate Professor in the\nUniversity of Toronto Department of Medical Biophysics\, Senior Scientist at the Princess Margaret Cancer Centre\, and Senior Investigator at the Ontario Institute for Cancer Research. His research lab is focused on understanding clinical implications of clonal shifts in cancer and non-cancerous cell populations during treatment\, most recently using cell-free DNA\, immune repertoire\, and single cell RNA-seq sequencing.\nMost recently\, he was recognized by Canada’s Top 40 Under 40\, the Canadian Cancer Society Bernard and Francine Dorval Prize\, a Terry Fox New Investigator Award\, and inclusion on the Web of Science Highly Cited Researchers List (top 1% of citations by field internationally).
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-november-2022/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221028T120000
DTEND;TZID=America/Toronto:20221028T130000
DTSTAMP:20260626T141116
CREATED:20220902T210306Z
LAST-MODIFIED:20221019T213712Z
UID:10000009-1666958400-1666962000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series October 2022
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \n \nOctober 28 – RNA Sequencing In The Clinical Laboratory: The Sickkids Experience\nIn recent years\, the use of next-generation sequencing (NGS) and the ability to sequence the entire genome has increased the diagnostic rate for both rare diseases and cancer. However\, despite rapid advances in our understanding of the human genome\, nearly two-thirds of the patients with suspected rare genetic disorders remain without a conclusive molecular genetic diagnosis. RNA sequencing has the potential to improve our ability to interpret the functional and clinical significance of the genetic variants. We will review the role of RNA sequencing in a number of clinical scenarios and the path to developing and integrating innovative whole transcriptome analysis in clinical diagnostics. \nLearning objectives:\nDescribe the path to developing and implementing RNA sequencing in the clinical laboratory\nIdentify current and future clinical applications of RNA sequencing \nTarget audience: Geneticists\, Trainees\nCanMEDS Roles: Medical Expert (the integrating role)\, Collaborator\, Health Advocate\, Scholar\, Professional \n  \nBio\nDr. Lianna Kyriakopoulou is currently a director of Genome Diagnostics at the Hospital for Sick Children and Assistant Professor at the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She received her PhD in Microbiology and Molecular and Medical Genetics from the University of Toronto. She is certified by the Canadian Academy of Clinical Biochemistry and the American College of Medical Genetics in Clinical Molecular Genetics. Dr. Kyriakopoulou’s professional interests are in the areas of genetic metabolic disorders and diagnostic assay development using high-throughput methodologies and genomic tests\, particularly for rare disorders. \nAll Dates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-october-2022/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220923T120000
DTEND;TZID=America/Toronto:20220923T130000
DTSTAMP:20260626T141116
CREATED:20220902T210107Z
LAST-MODIFIED:20220920T205745Z
UID:10000008-1663934400-1663938000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG - The Leading Strand Series September 2022
DESCRIPTION:Seeking Equity For Precision Diagnosis Through The Silent Genome Project-governance\, Diagnostic And Bioinformatic Highlights With The Introduction Of Cafe (cohort Allele Frequency Estimation Pipeline). \nSummary:\nDrs Arbour and Wasserman will provide an overview of the progress of Silent Genomes Project to date including governance\, diagnostic and bioinformatic highlights on the path to build a sustainable Indigenous Background Variant Library. \nObjectives: \n\nIdentify on-going barriers to achieving equitable genetics/genomics care for Indigenous patients.\nDescribe challenges and potential solutions presented through the Silent Genome Project to provide equitable precision diagnosis for Indigenous patients.\nLearn about a protected\, sustainable solution to housing Indigenous specific genomic reference data in Canada.\n\nThis series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nDates \nSeptember 23\nOctober 28\nNovember 25\nDecember 16\nJanuary 27\nFebruary 24\nMarch 31\nApril 28\nMay 26\nJune 30 \nClick HERE to register. \nSpeaker bios \nDr. Laura Arbour is a Professor in the Department of Medical Genetics at the University of British Columbia\, situated at the Island Medical Program on Vancouver Island. Trained as both pediatrician and clinical geneticist (McGill University) her multifaceted Community Genetics Research Program addresses rare\, single gene disorders and complex conditions affecting Indigenous people. Her clinical practice encompasses rare genetic disease diagnosis and cardio-genetics. Her Northern BC work on Long QT syndrome led to the development of the BC Inherited Arrhythmia Program (BCIAP) for all British Columbians with inherited arrhythmias. She is also the project lead on a Genome Canada/Genome BC/CIHR funded Large Scale Applied Research Project\, entitled “Silent Genomes: Reducing health-care disparities and improving diagnostic success for Indigenous children with genetic disease” which aims to address the challenges of equitable access to genetic/genomic diagnosis and care for Canadian Indigenous populations. \n A professor in the Department of Medical Genetics at the University of British Columbia and based at BC Children’s Hospital\, Dr. Wyeth Wasserman’s computational biology research focuses on the analysis of the human genome. His laboratory conducts research in two overlapping domains: the control of gene activity and the identification of the causes of rare genetic disorders. His lab created the JASPAR database and a wide range of software which are used globally to identify the “on/off” switches in genes. Since low-cost DNA sequencing became accessible for patients\, his team works closely with clinicians at BC Children’s Hospital to discover the genetic causes impacting patients and families. He is a co-lead for the Silent Genomes Project and the lead for Activity 3\, the Development of an Indigenous Background Variant Library.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-september-2022/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
END:VCALENDAR